Envigo adds Craig Boyd and Lizanne Muller

Friday, September 22, 2017

Envigo has made two new appointments to its Executive Committee. The appointments of a Chief Commercial Officer and President of EMEA Operations have been made at a time of growth for Envigo during which the organization has been focused on improving the quality of the customer experience for its global customer base across the pharmaceutical, chemicals, and crop protection industries. Both of the positions report directly into Dr. Adrian Hardy, Chief Executive Officer of Envigo.

[Read More]

AHPAC to combine with Envigo International

Friday, August 25, 2017

Avista Healthcare Public Acquisition Corp. (AHPAC), a publicly traded special purpose acquisition company, and Envigo International Holdings, an early stage non-clinical CRO offering a diverse set of non-clinical discovery and safety assessment services as well as laboratory animal science tools, jointly announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Envigo will become a wholly-owned subsidiary of AHPAC, which will be re-named Envigo International Holdings, Inc. and is expected to be listed on the NASDAQ stock exchange as of closing of the proposed transaction.

[Read More]

Envigo facilities in Hyderabad, India gain AAALAC accreditation

Monday, June 5, 2017

Envigo has announced that its Research Models and Services (RMS) facility in Hyderabad, India, has been granted full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. In a letter to Envigo, AAALAC notified the company that it had met all the conditions required for full accreditation and commended the high quality facility and expertise of its people.

[Read More]

Envigo expands R&D capabilities for in vitro assays

Friday, March 17, 2017

Envigo announces that it will develop and internally validate five to seven ion channel In vitro tests for measuring cardiac risk potential ahead of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) recommendations expected at the end of this year. These assays will form an integrated suite of tests that include the company’s existing hERG (Human Ether-à-go-go-Related Gene) assay.

[Read More]

Envigo launches hepatotoxicity testing for drug development de-risking program

Monday, November 7, 2016

Envigo has launched an integrated program of in vitro technologies that help predict the likelihood of compounds causing drug induced livery injury (DILI)—one of the major causes of drugs being withdrawn from the market. Since 1980, over 30 drugs have been withdrawn because of hepatotoxicity with many others having severe restrictions placed upon their use. As a consequence, and to help minimize any risks to patients taking their medicines, the pharma industry is concerned not to progress compounds that show any potential DILI liability.

[Read More]

Envigo appoints Hardy president and CEO, Cass executive chairman

Monday, June 27, 2016

Envigo has announced that its board of directors has appointed Dr. Adrian Hardy as president and chief executive officer, effective July 1. He will join the company’s board of directors. Dr. Hardy joined Envigo in 2002 and has held various roles of increasing responsibility in sales, strategic marketing and operations, most recently serving as COO. 

[Read More]

Envigo appoints Scott Schulz Director of North American Operations

Thursday, May 26, 2016

Envigo has appointed Scott Schulz, MBA, to the post of director, North American (NA) Operations. In this role, Schulz will optimize operational performance and service delivery across the company’s North American based production locations for Research Models and Services (RMS). He will report directly to Michael Caulfield, president North American RMS at Envigo.

[Read More]